A Phase 2 interventional study of Semaglutide 2.4 mg and Cagrilintide 2.4 mg in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 2, and was the 1st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 7 more countries
Ages 10–18
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2021.
This study's enrollment of 92 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 274 across the 15 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 274th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 37 in phase 2, and was the 539th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
2 of the studies testing cagrilintide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.
Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.
Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance.
A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected.
Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how.
The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor.
At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed).
Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
Drug: Semaglutide 2.4 mg · Drug: Cagrilintide 2.4 mg
Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
Drug: Cagrilintide 2.4 mg · Drug: Placebo (semaglutide)
Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks
Drug: Semaglutide 2.4 mg · Drug: Placebo (cagrilintide)
Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site. The on-treatment without rescue medication period is a subset of the 'on-treatment' observation period and represents the time period where subjects are considered exposed to trial product but have not initiated any rescue medications.
Time frame: Week 0, Week 32
Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: Week 0, Week 32
Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Percenatge change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: Week 0, Week 32
Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: Week 0, Week 32
Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide)
Change in FPG from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: Week 0, Week 32
CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Change in mean glucose from baslline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: Week 0, Week 32
Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of TAR greater than 10.0 mmol/L (greater than 180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range greater than 10.0 mmol/L (greater than 180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: At week 32
Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide)
Percentage of TIR 3.9-10.0 mmol/L (70-180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
Time frame: At week 32
Number of Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical trial participants administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.
Time frame: From baseline (week 0) to week 37
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 37 are presented. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.
Time frame: From baseline (week 0) to week 37
The trial was conducted at 17 sites in the United States.
| Milestone | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|---|
| Started | 31 | 30 | 31 |
| Completed | 29 | 30 | 29 |
| Not completed | 2 | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 |
Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site. The on-treatment without rescue medication period is a subset of the 'on-treatment' observation period and represents the time period where subjects are considered exposed to trial product but have not initiated any rescue medications.
| Percentage of HbA1c | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|
| Change from Baseline - in-trial | -2.2 ± 0.9 | -1.9 ± 1.0 |
| Change from Baseline - on treatment without rescue | -2.2 ± 0.9 | -2.0 ± 1.0 |
Change in HbA1c from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Percentage point of HbA1c | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | -2.2 ± 0.9 | -0.8 ± 0.9 |
Percenatge change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Percentage of body weight | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|
| Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | -14.7 ± 9.3 | -5.0 ± 4.0 |
Change in body weight from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Kilogram | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|
| Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | -15.4 ± 10.1 | -5.3 ± 4.2 |
Change in FPG from baseline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Millimoles per liter (mmol/L) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | -3.4 ± 3.1 | -2.7 ± 2.3 |
Change in mean glucose from baslline (week 0) to week 32 is presented. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Millimoles per liter (mmol/l) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) |
|---|---|---|
| CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | -3.5 ± 2.3 | -1.0 ± 2.2 |
Percentage of TAR greater than 10.0 mmol/L (greater than 180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range greater than 10.0 mmol/L (greater than 180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Percentage of time | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) |
|---|---|---|
| Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | 10.3 ± 15.7 | 30.9 ± 25.2 |
Percentage of TIR 3.9-10.0 mmol/L (70-180 mg/dL) at week 32 is presented. The percentage of time spent in glycaemic target range was calculated as 100 times the number of recorded measurements in glycaemic target range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive divided by the total number of recorded measurements. The endpoint was evaluated based on the data from in-trial period. The in-trial period is defined as the time interval from date of randomization to date of last contact with trial site.
| Percentage of time | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) |
|---|---|---|
| Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | 88.9 ± 15.3 | 68.9 ± 25.1 |
An adverse event (AE) is any untoward medical occurrence in a clinical trial participants administered or using a medicinal product, whether or not considered related to the medicinal product or usage. A TEAE was defined as an event that had onset date (or increase in severity) during the on-treatment observation period. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.
| Events | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAEs) | 21 | 24 | 22 |
Clinically significant hypoglycaemic episodes (level 2) were defined as episodes that were sufficiently low to indicate serious, clinically important hypoglycaemia with plasma glucose value of less than (\<) 3.0 mmol/L (54 mg/dL). Severe hypoglycaemic episodes (level 3) were defined as episodes that were associated with severe cognitive impairment requiring external assistance for recovery. Number of clinically significant hypoglycaemic episodes (level 2), confirmed by blood glucose (BG) meter or severe hypoglycaemic episodes (level 3) that occurred from week 0 to week 37 are presented. On treatment observation period starts at the date of first dose of trial product and ends at the first date of any of the following; the date of last dose of trial product +35 days for AEs and hypoglycaemic episodes/+ 14 days for other endpoints; the end-date for the 'in-trial' observation period.
| Episodes | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|---|
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | 0 | 0 | 0 |
Collected over From baseline (week 0) to week 37. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cagrilintide 2.4 mg + Semaglutide 2.4 mg | 0/31 (0%) | 0/31 (0%) | 18/31 (58.1%) |
| Cagrilintide 2.4 mg + Placebo (Semaglutide) | 0/30 (0%) | 4/30 (13.3%) | 18/30 (60%) |
| Semaglutide 2.4 mg + Placebo (Cagrilintide) | 0/31 (0%) | 2/31 (6.5%) | 18/31 (58.1%) |
| Event | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/31 | 1/30 | 0/31 |
| Chest painGeneral disorders | 0/31 | 1/30 | 0/31 |
| Coronary artery diseaseCardiac disorders | 0/31 | 1/30 | 0/31 |
| Deep vein thrombosisVascular disorders | 0/31 | 1/30 | 0/31 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/31 | 1/30 | 0/31 |
| HypotensionVascular disorders | 0/31 | 0/30 | 1/31 |
| Loss of consciousnessNervous system disorders | 0/31 | 0/30 | 1/31 |
| Event | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 9/31 | 4/30 | 5/31 |
| COVID-19Infections and infestations | 5/31 | 5/30 | 3/31 |
| ConstipationGastrointestinal disorders | 5/31 | 4/30 | 4/31 |
| DiarrhoeaGastrointestinal disorders | 5/31 | 2/30 | 2/31 |
| HeadacheNervous system disorders | 0/31 | 3/30 | 3/31 |
| ConjunctivitisInfections and infestations | 0/31 | 0/30 | 3/31 |
| FatigueGeneral disorders | 3/31 | 1/30 | 0/31 |
| GastroenteritisInfections and infestations | 2/31 | 1/30 | 3/31 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 3/31 | 1/30 | 0/31 |
| Upper respiratory tract infectionInfections and infestations | 2/31 | 2/30 | 3/31 |
Full analyis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) | Total |
|---|---|---|---|---|
| Mean | 56 ± 10 | 62 ± 7 | 57 ± 10 | 58 ± 9 |
| Sex: Female, Male(Participants) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) | Total |
|---|---|---|---|---|
| Female | 13 | 7 | 13 | 33 |
| Male | 18 | 23 | 18 | 59 |
| Ethnicity (NIH/OMB)(Participants) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 10 | 6 | 13 | 29 |
| Not Hispanic or Latino | 21 | 24 | 18 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cagrilintide 2.4 mg + Semaglutide 2.4 mg | Cagrilintide 2.4 mg + Placebo (Semaglutide) | Semaglutide 2.4 mg + Placebo (Cagrilintide) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 5 | 5 | 5 | 15 |
| White | 26 | 22 | 24 | 72 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Aug 2021 to primary completion in Jul 2022, 11 months.
Results were first posted in Jul 2023, 1 year after primary completion.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide